PCSK9 inhibitors: the new blockbusters in cholesterol lowering therapy?
Research published in BMC Medicine looks at the new therapeutic strategy for lowering the ‘bad’ cholesterol levels and its link with cardiovascular disease.… Read more »
Dr Evangelos Liberopoulos is Assistant Professor in Internal Medicine in the University of Ioannina School of Health Sciences-Faculty of Medicine, Ioannina, Greece. He is an expert in lipid and metabolic diseases. He is currently the national coordinator for the ODYSSEY OUTCOMES trial (https://clinicaltrials.gov/ct2/show/NCT01663402) in Greece.
Latest posts by Evangelos Liberopoulos (see all)